약학회지
YAKHAK HOEJI
ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 1.

Table. 1.

PPI drugs included in the analysis

Pantoprazole Rabeprazole Omeprazole Esomeprazole Lansoprazole
Marketed date 1999/04 2000/02 1989/02 2000/10 1999/12

Generic listed date 2007/09 2007/01 prior to 2001 2014/10 2011/09

Formulation (NHI code) Tablet, Injection (208801ATE, 208801BIJ, 208802ATE) Tablet (222201ATE, 222202ATE) Capsule, Injection (204401ACE) Tablet, Injection (367201ACH, 367202ACH, 367201ATB, 367202ATB) Capsule (181301ACE, 181302ACE)

DDD 40mg 20mg 20mg 30mg 30mg

Indication Low dose (20mg) High dose (40mg) Low dose (5mg) High dose (10,20mg) Gastric ulcer, Duodenal ulcer, Ulcer prevention, GERD, Helicobacter pylori eradication, prevention of NSAIDs’ complications Ulcer prevention, GERD, Helicobacter pylori eradication, prevention of NSAIDs’ complications Gastric ulcer, Duodenal ulcer, Ulcer prevention, GERD, Helicobacter pylori eradication, prevention of NSAIDs’ complications

Ulcer prevention, GERD, prevention of NSAIDs’ complications Gastric ulcer, Duodenal ulcer, GERD, Helicobacter pylori eradication NSAIDs prevention Gastric ulcer, Duodenal ulcer, GERD, Helicobacter pylori eradication

DDD: Defined Daily Dose

GERD: Gastroesophageal reflux disease

NSAIDs: non-steroidal anti-inflammatory drugs

NHI code: The drug codes included in this study mean main ingredient code designated by National Health Insurance Reimbursement Schedule

Yakhak Hoeji 2021;65:276-83 https://doi.org/10.17480/psk.2021.65.4.276
© 2021 Yakhak Hoeji